BioCentury
ARTICLE | Company News

Nerviano, Servier deal

August 5, 2013 7:00 AM UTC

Servier paid Nerviano €8 million ($10.6 million) in exchange for an option to license worldwide rights to develop and commercialize preclinical compounds from Nerviano that inhibit TTK protein kinase (TTK; MPS1), a cell cycle regulator. Servier said preclinical data suggest TTK may "represent an attractive therapeutic target in a poor prognosis associated subgroup of breast cancer." ...